Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2025-04-07 00:00:00 ET · period of report 2025-04-04 · accession 0001415889-25-010290 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-07 | 2025-04-04 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +49.4K | 302.2K | +20% | +$14.8K |
| D | 2025-04-07 | 2025-04-04 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.00 | -49.4K | 252.4K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-04 | M | A | 49,367 | $0.3 | 302,223 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-04-04 | M | D | 49,367 | $0.00 | 252,444 | D | $0.3 · — to 2028-03-25 | 49,367 Common Stock | (F1) Immediately exercisable. |